Search

This article highlights the increasing challenges faced by the innovator companies owing to pre-grant opposition proceedings in Pakistan. On one hand, the generic drug makers are using the system as a legal tool to frustrate the process of patent grant, while on the other paralysing the innovator companies from initiating patent infringement proceedings against them. In the recent opposition proceedings between Otsuks and Pharmatec, the Pakistan Patent Office had correctly applied the relevant provisions of the Patents Ordinance 2000 to decide the question of limitation, but failed to apply its judicial wisdom while denying protection to Otsuka patent application relating to an improved process for preparing aripiprazole when opposed by the generic drug maker-- Pharmatec. Fluctuation in the decision at the ex parte stage and after opposition are unveiling interesting parallels and providing a guideline helping innovator companies and equally the generics in future patent-related conflicts. [ABSTRACT FROM AUTHOR]